505 Eagleview Boulevard,
Suite 212, Exton, PA, 19341

3 January 2022

European Medicines Agency
EudraCT Registration Team
Domenico Scarlattilaan 6
HS Amsterdam
Zuid
1083 HS

Sponsor:	Idera Pharmaceuticals, Inc.
Protocol no.:	2125-MEL-301
Protocol Title:	A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma
EudraCT no.:	2017-002454-36

Dear EudraCT Team:

The 2125-MEL-301 trial entitled "A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma" was prematurely ended. The co-primary endpoint for the objective response rate (ORR) for tilsotolimod was not met under IND 125515, Eudra CT No 2017-002454-36 as announced by the Sponsor in a press release on March 18, 2021. Based on the totality of data reviewed from the database lock for ORR, Idera discontinued the study and did not proceed to the second co-primary endpoint of overall survival (OS). Consequently, the last patient's last visit was 1 June 2021. There were no new safety issues or trends identified.

Best regards,

DocuSigned by:
Lauren K Colfer
4C40FBF7E06844B...

Lauren K Colfer

Head of Clinical Operations

Idera Pharmaceuticals, Inc.